|
n = 22
| |
Mean ± S.D.
|
Median
|
Range
|
|---|
|
Age (year)
| |
66.09 ± 7.78
|
65
|
51–80
|
|
Sex
|
|
Male
|
17
| | | |
|
Female
|
5
|
|
Body Height (cm)
| |
162.84 ± 8.35
|
163.35
|
149.00–175.30
|
|
Body Weight (kg)
| |
58.14 ± 9.11
|
56.55
|
40.00–74.00
|
|
PS
|
|
0
|
14
| | | |
|
1
|
6
|
|
2<
|
2
|
|
Type of cancer
|
|
Colon
|
13
| | | |
|
Rectal
|
7
|
|
Cecum
|
2
|
|
EGFR-targeting antibodies
|
|
Cetuximab
|
14
| | | |
|
Panitumumab
|
8
|
|
No metastatic sites
|
|
One
|
7
| | | |
|
Two
|
8
|
|
Three or more
|
7
|
|
Involved sites
|
6
| | | |
|
Lung
|
13
| | | |
|
Liver
|
14
|
|
Lymph nodes
|
3
|
|
Bone
|
0
|
|
Peritoneal
|
7
|
|
Median treatment cycle
| | |
9.30
|
1.00–23.00
|
|
Median treatment duration, weeks
| | |
9.00
|
2.00–46.00
|
|
Combination of Magnesium oxide formulation
|
|
Yes
|
11
| | | |
|
No
|
11
|
|
Combination regimen
|
|
FOLFIRI base
|
15
| | | |
|
FOLFOX base
|
2
|
|
CPT-11
|
2
|
|
Monotherapy
|
3
|
|
Serum Magnesium (mg/dL)
| |
2.13 ± 0.22
|
2.00
|
1.80–2.60
|
|
Serum Calcium (mg/dL)
| |
9.96 ± 0.33
|
9.85
|
9.50–10.50
|
|
Laboratory data
|
|
Neu (/mm3)
| |
3716.8 ± 1459.1
|
3475.0
|
1380.0–6880.0
|
|
WBC (/mm3)
| |
5936.3 ± 1685.9
|
5450.0
|
3200.0–10100.0
|
|
PLT (/mm3)
| |
207,091 ± 5651
|
205,500
|
111,000–330,000
|
|
Hb (g/dl)
| |
11.67 ± 1.73
|
11.55
|
7.80–14.4
|
|
sCre (mg/dl)
| |
0.73 ± 0.31
|
0.64
|
0.51–1.88
|
|
AST (IU/l)
| |
20.40 ± 4.44
|
21.00
|
12.00–28.00
|
|
ALT (IU/l)
| |
15.40 ± 7.08
|
13.50
|
5.00–30.00
|
- Patients treated with anti-EGFR antibodies = 43; serum Ca level was measured for all patients
